Fig. 2: Smoldering multiple myeloma cohort included in the study. | Blood Cancer Journal

Fig. 2: Smoldering multiple myeloma cohort included in the study.

From: The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?

Fig. 2

Those SMM patients with a serum M-protein of ≥3 g/dL or urinary M-protein ≥ 500 mg per 24 h were classified as “myeloma-like” with the remaining patients classified as “MGUS-like.” MM multiple myeloma, SMM smoldering multiple myeloma, MGUS monoclonal gammopathy of undetermined significance, Int intermediate, LR low risk, IR intermediate risk, HR high risk. An asterisk (*) represents patients’ missing data for SMM and MGUS risk stratification.

Back to article page